I'd also like to know, but Adcetris apparently also has worked, quite coincidentally, on other auto-immune disorders. A substantial paper published in the July 28, 2014, edition of the journal Rheumotology described "a case of complete, sustained remission of RA [rheumatoid arthritis] on the novel CD30-directed antibody–drug conjugate (ADC) brentuximab vedotin" in a 76-year-old woman. "To our knowledge this has not previously been reported in the literature," the scientists wrote.
I do believe that this is potentially a very big development for us:
BOTHELL, Wash.--(BUSINESS WIRE)--Jul. 9, 2015-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the initiation of a phase 2 clinical trial evaluating ADCETRIS (brentuximab vedotin) in systemic lupus erythematosus (SLE, or lupus). Lupus is a chronic autoimmune disease in which the body’s own immune system overreacts and attacks healthy organs, causing inflammation, pain, permanent organ damage or death....According to the Lupus Foundation, an estimated 5 million people throughout the world have various forms of lupus and at least 1.5 million people in the U.S. are living with the disease.
Re a Unum IPO, this from Xconomy this morning: The company is moving at a fast pace. With the new cash, Unum has now raised some $77 million in two rounds since emerging from stealth last October. And the presence of crossover backers is as sure an indication as any that a startup is at least considering going public. There have been several such Series B rounds this year already from quickly maturing Boston-area biotechs like Jounce Therapeutics, Dimension Therapeutics, and Voyager Therapeutics.
Unum CEO Chuck Wilson confirmed to Xconomy that an IPO is on the radar, noting that the company’s intention in building this type of syndicate was “very much to position this as a crossover round to enable a future public financing.”
“Obviously the feasibility of an IPO will be dictated by continued progress and market conditions, but we do see it on the horizon,” Wilson says. “We’re intending to use the funding to support a number of fully-owned Unum programs through to clinical proof-of-concept—we see [that] happening over the next one to three years.”
I think we sometimes think a little too much. We've had a heckuva run. A pause is not a huge surprise. Also, many biotechs similarly are down today. (Totally agree about the Bakers. For years, they've been our canaries in the SGEN coal mine and they're doing just fine, as are we.)
Here, he uses mauihope, fsout, and back in the day, rickarooski, along with several others. He's quite transparent and easy to catch. It's sad, really. He isn't even any good at being a troll.
Yeah...pal..this is what was in your posts of May 1, when you supposedly were such a big buyer: Smelky post of May 1: "This Baker guy bought a million shares at 43 in December 2013.... he is taking a bath here ....All of his other SGEN trades are under water, but this purchase was the biggest gaffe." Another Smelky post of May 1: "82 million or say 350 million for the full year? give or take... Well, those numbers do not support a 5 billion dollar valuation....pretty clear why everyone is selling this down since Feb of 2014." A third Smelky post of May 1: It is no wonder the stock is being sold off for 15 months...Adcetris revenue trajection is paltry at best... Nothing in there but years of tiny licensing deals that will never amount to anything. Clay's stategy has failed investors...I repeat, SGEN will settle around 17 dollars a share... It won't get there for awhile, but rest assured, it is going to that level over time." And, in a fourth post that very same day, you said you were trimming, not buying.
Terrific analysis and thanks for sharing it. I was little concerned about the short-term market response to the news, but obviously that concern was misplaced. Years ago, this kind of good news would have triggered an inexplicable decline in share price, but those days seem over. This is another indication that SGEN truly has turned the corner as an investment, with even brighter days to come.
Yeah, sure you did. That's why you spent the last three months bashing. Give us a break.
Oh, Ye Troll of The Many Aliases: We haven't heard from you since around $34 or so. We know you're watching. Don't you think you should stop by and apologize? Wouldn't that be the decent thing to do? Isn't that what your parents taught you to do?
Agreed. It will open at the official 4 p.m. closing price of $42.99 (which someone worked hard to keep just below $43 at the final tick) and the news-less AH trading will have no effect.
Not recently, but GILD has been on pretty much every list of potential SGEN suitors (of which they are many). BTW, anyone seen or heard recently from theTroll of 1,000 Aliases, known here as rickarooski/fsout/mauihope/smelkykid/etc./etc.? Of course not. Try to remember this the next time the stock fades a bit and he/they show up to say "I told you so," even though he/they never actually told you so.
Just for fun, I'll weigh in. After holding quite a bit for nearly 10 years now, if I were asked - and I certainly would not be - I would happily take $80 a share now to avoid all risks later. Another advantage of taking a buyout now: I wouldn't have to keep discovering Ricky's new aliases and putting him/them on ignore. :)
The Bakers now own 24 percent of the company, will probably keep buying shares and sit on the board of directors. People who still short this stock deserve what's going to happen to them.
Actually, they just kept buying and buying during the last three days, all the way into the $37s.
Nothing huge to report. I heard nothing new, other than a few hints about attractive data poised to be released at ASH and at other conferences. But it was hard not to be impressed, all over again, with the depth and breadth of SGEN's pipeline and collaborations. Pretty easy to see why the Bakers are so heavily invested here.
Wow. Poor crazy, irrational Ricky/fstout/maul/smelky/etc. No longer satisfied with swapping aliases, now he's also swapping genders. Back on iggy with all of you. You don't need any more help from me. You've revealed yourself/yourselves quite completely. ("10 is 10.")